adg116
mAbexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 28, 2020 (NCT04111445)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05277402 | Phase 1 | Feb 9, 2022 | Adagene Inc, Merck |
| NCT04501276 | Phase 1 | Sep 23, 2020 | Adagene Inc |
| NCT04111445 | Phase 1 | Jan 28, 2020 | Adagene Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adagene Inc | For profit | 3 | 3 | 1 | 2020 |
| Merck | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1